|Bid||146.15 x 800|
|Ask||146.66 x 1300|
|Day's Range||144.39 - 148.04|
|52 Week Range||125.18 - 174.04|
|PE Ratio (TTM)||N/A|
|YTD Daily Total Return||-2.91%|
|Beta (5Y Monthly)||0.89|
|Expense Ratio (net)||0.46%|
BlackRock, Inc. (NYSE: BLK) today announced product enhancements to two iShares ETFs as part of an ongoing process to periodically review its product lineup.
Shares of Enveric Biosciences Inc. doubled in very heavy volume in midday trading Wednesday, after the Florida-based biotechnology company focused on cannabinoid-based treatments and cancer treatments said it acquired a perpetual license from Diverse Biotech for novel molecules for developing cancer treatments. Trading volume ballooned to 214.6 million shares, compared with the full-day average of about 2.4 million shares over the past 30 days. Enveric's stock, which was up 100%, was both the biggest gainer and most actively traded on major U.S. exchanges. "This is an exclusive, novel way of bringing together CBD and well-known, existing compounds that hold promise to create a new, improved drug class," added Enveric Chief Executive David Johnson. "As a patient-centric company, Enveric is constantly looking for new ways to eliminate or minimize cancer treatment side effects for patients in need." Enveric's stock has still lost 7.9% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 1.7% and the S&P 500 has gained 6.3%.
Shares of Ocugen Inc. soared 31.0% in premarket trading Wednesday, after the biopharmaceutical company said its co-development partner Bharat Biotech released an interim analysis of its Phase 3 trial of its COVID-19 vaccine candidate, COVAXIN, which demonstrated efficacy of 81%. Bharat's Phase 3 trial in India enrolled 25,800 participants aged 18 to 91, and the first interim analysis is based on 43 cases. A review of the safety database showed severe, serious and medically attended adverse events occurred at low levels and balanced between vaccine and placebo groups. "These results, which in part suggest significant immunogenicity against the rapidly emerging UK variant, represent an additional step towards outlining the regulatory pathway for EUA and approval in the United States," said Ocugen Chief Executive Shankar Musunuri. "COVAXIN, a whole virion based vaccine candidate, is designed to fill a significant unmet need in our national arsenal of vaccines against COVID-19." Ocugen's stock has skyrocketed 3,071.5% over the past three months, while the iShares Nasdaq Biotechnology ETF has tacked on 6.8% and the S&P 500 has gained 5.6%.